BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.290
+0.030 (2.38%)
May 5, 2026, 12:48 PM EDT - Market open
BioXcel Therapeutics Employees
BioXcel Therapeutics had 29 employees as of December 31, 2025. The number of employees decreased by 8 or -21.62% compared to the previous year.
Employees
29
Change (1Y)
-8
Growth (1Y)
-21.62%
Revenue / Employee
$22,138
Profits / Employee
-$2,410,241
Market Cap
34.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | -8 | -21.62% |
| Dec 31, 2024 | 37 | -37 | -50.00% |
| Dec 31, 2023 | 74 | -109 | -59.56% |
| Dec 31, 2022 | 183 | 94 | 105.62% |
| Dec 31, 2021 | 89 | 39 | 78.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| China Pharma Holdings | 215 |
| Rockwell Medical | 157 |
| Aytu BioPharma | 83 |
| Talphera | 12 |
| Incannex Healthcare | 12 |
| TherapeuticsMD | 1 |
BTAI News
- 11 days ago - BioXcel Therapeutics Transcript: Investor update - Transcripts
- 18 days ago - BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - GlobeNewsWire
- 25 days ago - Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 27 days ago - BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - GlobeNewsWire
- 4 weeks ago - BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - GlobeNewsWire
- 5 weeks ago - BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - GlobeNewsWire
- 7 weeks ago - BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - GlobeNewsWire